

18 Jul 2022 | Analysis

Podcast Special: The Shifting Landscape For Drugs And Devices Post-Roe v. Wade

by [Marion Webb](#)

A special podcast looks at the implications for FDA-regulated sectors, from the abortion pill and OTC daily and emergency contraceptives to intrauterine devices and period-tracking apps, of the US Supreme Court's historic overturning of Roe v. Wade.

Listen to the podcast below:

[Click here to explore this interactive content online](#) ✎

Articles discussed in this podcast:

- [US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application](#)
- [Allowing States To Ban Abortion Services Increases Calls For Making Birth Control Available OTC](#)
- [OTC Switch For Daily Oral Contraceptive Brandished In Senate Health Care Policy Duel](#)
- [Barriers To US OTC Emergency Contraceptive Sales Remain Despite Court Rebuke Of Restrictions](#)
- [Expanding US OTC Switches Turns On Flexibility In FDA Drug Approval Process And For Consumers](#)
- [Dual Rx/OTC Status In US 'Additional Condition' Switch Proposal: Necessary Or Questionable?](#)

PINK SHEET

CITELINE REGULATORY

- [US FDA May Play Central Role In Assuring Access To Mifepristone Post Roe v. Wade](#)
- [Mifepristone Access Imperiled By Supreme Court's Draft Decision Overturning Abortion Rights](#)
- [With Roe v. Wade In Rearview, What's Next For Women's Health](#)
- [Telemedicine Among Sticky Wickets As Uncertainty Abounds Post-Roe v. Wade](#)
- [Period-Tracking Apps Should Safeguard Data, Reassure Customers In Post-Roe Era](#)

Find more episodes on the *Medtech Insight* [podcast page](#). These and other Informa Pharma Intelligence podcasts also are available on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#), and [Spotify Podcasts](#), as well as smart speakers if the platforms have been set up as the default podcast provider.